<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520959</url>
  </required_header>
  <id_info>
    <org_study_id>IMDZ-04-1702</org_study_id>
    <nct_id>NCT03520959</nct_id>
  </id_info>
  <brief_title>Synovate Study for Synovial Sarcoma</brief_title>
  <official_title>A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally Advanced or Metastatic NY ESO 1+ Synovial Sarcoma Subjects Following First Line Systemic Anti Cancer Therapy (Synovate Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Design</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immune Design</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the
      growth of synovial sarcoma tumor and improve survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Synovate Study is a global, randomized, double-blind, placebo-controlled, phase 3 study
      in patients with unresectable, locally-advanced or metastatic NY-ESO-1 positive synovial
      sarcoma following first-line systemic anti-cancer therapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.</time_frame>
    <description>PFS by investigator-determined using RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization to date of death, assessed up to 66 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment</measure>
    <time_frame>From last dose of CMB305 to initiation of new therapy, assessed up to 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis Free Survival</measure>
    <time_frame>From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>From randomization to investigator-determined date of disease progression, assessed up to 24 months.</time_frame>
    <description>ORR defined by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety of CMB305 vs. placebo]</measure>
    <time_frame>From randomization to investigator-determined date of disease progression or death, assessed up to 24 months.</time_frame>
    <description>Safety will be assessed primarily based on reported adverse events (AEs), Medical events of interest (MEOIs), laboratory values, and concomitant medications reported from initiation of treatment with CMB305 or placebo. Medical events of interest, immune-mediated events, and AEs that occur more than 30 days after the last dose, and that are deemed as related to the study drug, will be included as TEAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>From Day 1 to 12 months post</time_frame>
    <description>Patient self reported measure of quality of life using the EQ-5D Instrument between the active treatment and placebo arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Synovial Sarcoma</condition>
  <condition>Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Sarcoma</condition>
  <condition>Metastatic Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CMB305 Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CMB305</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMB305</intervention_name>
    <description>Sequentially administered LV305 [lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene] and G305 [NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}]</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>CMB305 placebo control</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selected Inclusion Criteria:

          -  Histological diagnosis of synovial sarcoma

          -  Immunohistochemistry (IHC) results from tumor biopsy for NY-ESO-1 positive

          -  Subjects have received at least 4 but no more than 8 cycles of first-line
             anthracycline or ifosfamide containing systemic anti-cancer therapy regimen

          -  Must have documentation of no evidence of disease progression of the tumor during or
             after completion of first line systemic anti-cancer therapy

          -  ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1

          -  Age &gt;/= 12 years

          -  Life expectancy of at least 6 months

        Selected Exclusion Criteria:

          -  Have received last dose of first-line systemic anti-cancer therapy or date of most
             recent local regional therapy &gt;28 days prior to day 1

          -  Have received prior NY-ESO-1 therapy

          -  Have received first-line systemic anti-cancer therapy with an agent other than
             anthracycline or ifosfamide

          -  Have received treatment with systemic immunomodulatory agents within 28 days prior to
             administration of the first dose of CMB305, or 5 half-lives of the drug, whichever
             occurs sooner.

          -  Have significant immunosuppression from concurrent, recent, or anticipated need for
             chronic treatment with systemic immunosuppressive dose of corticosteroids or
             immunosuppressive medications.

          -  Have psychiatric or other medical illness, or any other condition that in the opinion
             of the investigator prevents compliance with the study procedures or ability to
             provide valid informed consent.

          -  Have history of uncontrolled autoimmune disease.

          -  Have a significant electrocardiogram finding or cardiovascular disease

          -  have inadequate organ function per protocol

          -  History of other cancer within 3 years

          -  Evidence of active tuberculosis or recent clinically-significant infection requiring
             systemic therapy.

          -  Evidence of active HepB, HepC, or HIV infection

          -  Have a history of brain metastasis

          -  Have received cancer therapies including chemotherapy, radiation, biologic, or kinase
             inhibitors, G-CSF, or GM-CSF within 3 weeks prior ot the first scheduled dose of
             CMB305

          -  Female of child bearing potential who is pregnant, is planning to become pregnant, or
             is breast feeding; or male who is sexually active with a female of child bearing
             potential who is planning to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>650.392.8306</phone>
    <email>MedicalMonitor1702@immunedesign.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Synovate Study</keyword>
  <keyword>NY-ESO-1</keyword>
  <keyword>cancer vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

